Genmab A/S (NASDAQ:GMAB)‘s stock had its “hold” rating reaffirmed by analysts at HC Wainwright in a report issued on Monday, Price Targets.com reports. They currently have a $47.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 9.46% from the stock’s previous close.
A number of other analysts have also recently commented on the stock. Royal Bank of Canada upped their price objective on shares of Genmab A/S from $46.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, August 12th. TheStreet upgraded shares of Genmab A/S from a “c” rating to a “b” rating in a research report on Monday, May 24th. Jefferies Financial Group cut shares of Genmab A/S from a “buy” rating to a “hold” rating and upped their price objective for the company from $45.50 to $48.00 in a research report on Thursday, September 16th. Morgan Stanley cut shares of Genmab A/S from an “equal weight” rating to an “underweight” rating and set a $37.00 price objective for the company. in a research report on Tuesday, September 7th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Genmab A/S in a research note on Friday, August 20th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $45.00.
GMAB opened at $42.94 on Monday. Genmab A/S has a 12 month low of $30.10 and a 12 month high of $49.07. The company has a fifty day simple moving average of $45.53 and a 200 day simple moving average of $40.42. The stock has a market cap of $28.20 billion, a P/E ratio of 69.26, a P/E/G ratio of 2.83 and a beta of 0.89.
Genmab A/S Company Profile
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
Read More: Dual Listing What You Need to Know
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.